The Cigna Group (CI) Stock Price & How to Invest

The Cigna Group is a large US health-services company built around two main engines. Its Evernorth health-services arm includes Express Scripts, one of the largest pharmacy benefit managers (PBMs) in the country, plus specialty pharmacy, care services, and pharmacy-related businesses; this is now the larger revenue and growth driver. Its Cigna Healthcare arm sells commercial health insurance, primarily to employers and individuals, along with international and supplemental coverage. Cigna makes money by collecting insurance premiums and managing medical costs, and by earning fees and spreads on managing drug benefits, negotiating with manufacturers, and dispensing specialty medications at scale. After exiting most of its Medicare businesses, Cigna is increasingly weighted toward commercial insurance and pharmacy services rather than government programs. It is headquartered in Bloomfield, Connecticut, and serves employers, health plans, government entities, and individuals.

In 2026 the results have been steady rather than dramatic. Second-quarter 2026 revenue was about $71.7 billion and GAAP net income about $1.66 billion; adjusted EPS of $7.78 beat the ~$7.60 consensus, the fourth straight quarter Cigna has edged past estimates. Trailing twelve-month revenue is about $282 billion, up from $274.9 billion for full-year 2025, and trailing net income about $6.4 billion. The balance sheet carries roughly $31.9 billion of debt against $7.3 billion of cash, and the business produced about $8 billion of free cash flow over the last year. As of October 16, 2026, the stock closed near $301.74, up about 8% year to date and about 4% over twelve months, close to the top of a 52-week range of roughly $240 to $311. The 24 analysts tracked by Yahoo Finance rate it a buy with a mean target near $342. Third-quarter results are scheduled for November 5, 2026, with consensus adjusted EPS of about $7.51 on roughly $72.5 billion of revenue, a slight year-over-year decline in EPS that analysts expect to reverse in 2027 (consensus ~$33.48, up about 10%).

Cigna faces significant regulatory and political risk: PBMs are under scrutiny from Congress, the FTC, and states over drug-pricing practices and rebate models, and potential reform could pressure the economics of Express Scripts. Health insurers also face rising medical-cost trends and utilization, which can squeeze margins. Concentration in a few large clients (including a major contract with Centene-related and Cigna's own plans) and reliance on retaining big PBM clients add risk. Drug-pricing reform, GLP-1 cost dynamics, litigation, and competitive pressure from vertically integrated rivals like UnitedHealth and CVS all weigh on the outlook. Analysts expect adjusted EPS to dip slightly year over year in the second half of 2026 before recovering in 2027, so any slippage in that recovery would test the thesis. The balance sheet carries about $31.9 billion of debt. The stock often trades at a low multiple reflecting these regulatory overhangs, about 9-10 times forward earnings in October 2026.

24 analysts publish price targets on CI, averaging $342.29 against a $302.30 price as of October 2026, or +13.2%. The published targets run from $288.00 to $400.00, a moderate spread, and the ratings split 18 buy, 6 hold, 0 sell. Over the last six months there have been 8 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CI forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on The Cigna Group. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Evernorth and pharmacy services scale. Evernorth, anchored by Express Scripts, is Cigna's growth engine. The most optimistic published target, $400.00, assumes this works close to its best case.

The case against. Cigna faces significant regulatory and political risk: PBMs are under scrutiny from Congress, the FTC, and states over drug-pricing practices and rebate models, and potential reform could pressure the economics of Express Scripts. The most pessimistic target, $288.00, is roughly what CI is worth if this bites instead.

Read the full bull and bear case on CI, including what would have to change to break either one. Walnut is not an investment adviser.

No. The Cigna Group (CI) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see The Cigna Group's investor relations page or your broker.

• Revenue (TTM): ~$282 billion (inflated by pharmacy pass-through revenue); Q2 2026 ~$71.7 billion
• Net income (TTM): ~$6.4 billion; ~2.3% net margin, ~4% operating margin
• Adjusted EPS: Q2 2026 $7.78 vs ~$7.60 expected; 2026 consensus ~$30.51, 2027 ~$33.48
• P/E: ~12.5x trailing GAAP; ~9x on 2027 consensus
• Dividend: ~$6.24 a year, ~2.1% yield, ~25% payout
• Free cash flow (TTM): ~$8 billion, funding large buybacks
• Market cap: ~$80 billion at ~$302 a share
• Debt / cash: ~$31.9 billion / ~$7.3 billion

Cigna trades near 12.5 times trailing GAAP earnings and about 9 times analysts' 2027 adjusted estimate, a discount to the broad market that reflects PBM regulatory risk and the optically huge but low-margin pharmacy pass-through revenue. The bull case leans on steady adjusted EPS beats (four quarters running), about $8 billion of annual free cash flow and heavy buybacks; the discount is the market pricing in policy and drug-pricing uncertainty. Third-quarter results arrive November 5, 2026.

If you want CI exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to CI: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CI exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (VFLO), which spreads the position across many companies. Or build it into a focused thematic portfolio, so CI sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CI fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The Cigna Group (CI) is a PBM-and-insurance combination whose growth leans on Evernorth's pharmacy scale and the rising tide of specialty and GLP-1 drug spend. In a portfolio it behaves as a defensive, value-multiple healthcare holding with heavy buybacks, discounted by the market for PBM regulatory and drug-pricing-reform risk rather than for weak cash generation. At about 10 times analysts' 2026 adjusted EPS estimate, that discount is still in place in October 2026.

Whether CI is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CI a buy or a sell?, and where the stock could go from here in the CI stock forecast.

For income investors, whether CI pays a dividend and how the payout looks is covered in does CI pay a dividend? And to weigh CI against a peer, read the full side-by-side comparisons: CI vs UNH and CI vs ELV.